AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36773971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral 4-quadrant laparoscopic-assisted transversus abdominis plane (BLTAP) block
Number of subjects: 160
Study 36773971 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesia (SA)
Number of subjects: 160
Study 36773971 — intervention group
Group type: COMPARATOR
Intervention: Unilateral laparoscopic-assisted transversus abdominis plane (ULTAP) block
Number of subjects: 160
Study 36773971 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic group (bupivacaine)
Number of subjects: 160
Study 36774099 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 31
Study 36774099 — intervention group
Group type: COMPARATOR
Intervention: Comparator group (weight-stable participants)
Number of subjects: 31
Study 36774101 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed diet (Meal, Ready-to-Eat)
Number of subjects: 0
Study 36774101 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 0
Study 36774112 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbs and spices at doses of 0.5, 3.3, and 6.6 g/day
Number of subjects: 54
Study 36774120 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency of animal source food (ASF) intake
Number of subjects: 7564
Study 36774120 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fish intake
Number of subjects: 7564
Study 36774120 — intervention group
Group type: EXPERIMENTAL
Intervention: Any meat intake
Number of subjects: 7564
Study 36774120 — intervention group
Group type: EXPERIMENTAL
Intervention: Any egg intake
Number of subjects: 7564
Study 36774120 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dairy intake
Number of subjects: 7564
Study 36774155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebetralstat (600 mg)
Number of subjects: 68
Study 36774155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 36774205 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave amplitude exceeding the 95th percentile in lead III
Number of subjects: 2457
Study 36774205 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave amplitude exceeding the 95th percentile in lead aVR
Number of subjects: 2457
Study 36774205 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave amplitude exceeding the 95th percentile in lead V1
Number of subjects: 2457
Study 36774331 — intervention group
Group type: EXPERIMENTAL
Intervention: EuTCV
Number of subjects: 100
Study 36774331 — intervention group
Group type: COMPARATOR
Intervention: Typbar-TCV®
Number of subjects: 100
Study 36774444 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese visceral adiposity index (CVAI) in ERA patients
Number of subjects: 104
Study 36774444 — intervention group
Group type: EXPERIMENTAL
Intervention: High CVAI group
Number of subjects: 104
Study 36774444 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CVAI
Number of subjects: 104
Study 36774447 — intervention group
Group type: EXPERIMENTAL
Intervention: BC-Predict (risk stratification)
Number of subjects: 5901
Study 36774447 — intervention group
Group type: COMPARATOR
Intervention: Standard NHSBSP
Number of subjects: 5901
Study 36774462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia index (SI)
Number of subjects: 306
Study 36774521 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma-reduction training with patient narrative videos
Number of subjects: 162
Study 36774521 — intervention group
Group type: COMPARATOR
Intervention: Attention-control training without patient narratives
Number of subjects: 162
Study 36774546 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anxiety measured using a verbal numeric anxiety score (VNS)
Number of subjects: 49
Study 36774546 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of ovarian stimulation (number of follicles, blood estradiol, and progesterone levels)
Number of subjects: 49
Study 36774905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine at a dose of 6 mg/kg
Number of subjects: 30
Study 36774933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg IV every 2 weeks for 12 doses) plus Ipilimumab (1 mg/kg IV every 6 weeks for four doses)
Number of subjects: 816
Study 36774933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 816
Study 36774933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Number of subjects: 816
Study 36774935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg, max 25 mg)
Number of subjects: 1430
Study 36774935 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg, max 90 mg)
Number of subjects: 1430
Study 36774935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1430
Study 36774935 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1430
Study 36774994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab
Number of subjects: 777
Study 36775009 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Charge 5 and daily text messages
Number of subjects: 48
Study 36775009 — intervention group
Group type: COMPARATOR
Intervention: Fitbit Charge 5 and information on PA and sleep guidelines
Number of subjects: 48
Study 36775248 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36775296 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual health and genital hygiene behaviors in adolescent girls and young women with CP
Number of subjects: 163
Study 36775296 — intervention group
Group type: COMPARATOR
Intervention: Healthy women control group
Number of subjects: 163
Study 36775313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 23
Study 36775313 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 23
Study 36775313 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 23
Study 36775643 — intervention group
Group type: EXPERIMENTAL
Intervention: App 1
Number of subjects: 0
Study 36775643 — intervention group
Group type: EXPERIMENTAL
Intervention: App 2
Number of subjects: 0
Study 36775643 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36775798 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet (MAD)
Number of subjects: 16
Study 36775798 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonmodified higher carbohydrate diet)
Number of subjects: 16
Study 36775965 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min nap
Number of subjects: 32
Study 36775965 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min nap
Number of subjects: 32
Study 36775965 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min nap
Number of subjects: 32
Study 36775965 — intervention group
Group type: COMPARATOR
Intervention: Waking (control)
Number of subjects: 32
Study 36775965 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min to 60 min naps
Number of subjects: 32
Study 36775965 — intervention group
Group type: EXPERIMENTAL
Intervention: Naps (10 to 60 min)
Number of subjects: 32
Study 36775980 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatment with cardioprotective antidiabetic medication
Number of subjects: 3700
Study 36775980 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-reported factors in clinical decision-making
Number of subjects: 3700
Study 36776086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular-ocular reflex (VOR) gains measured via video head impulse test (vHIT) in patients with PSCC-BPPV
Number of subjects: 62
Study 36776086 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-phase velocity (SPV) of nystagmus observed during the Dix-Hallpike maneuver in the study group
Number of subjects: 62
Study 36776263 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-triggered CS
Number of subjects: 769
Study 36776263 — intervention group
Group type: COMPARATOR
Intervention: Non-VA-triggered CS
Number of subjects: 769
Study 36776263 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ischemic cardiomyopathy
Number of subjects: 769
Study 36776416 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-arm splinting
Number of subjects: 34
Study 36776416 — intervention group
Group type: COMPARATOR
Intervention: Above-elbow casting
Number of subjects: 34
Study 36776683 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients (n=314) with myocardial injury (n=34)
Number of subjects: 497
Study 36776683 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 negative patients (n=183) with myocardial injury (n=57)
Number of subjects: 497
Study 36776716 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 300
Study 36777399 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 72
Study 36777426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 0
Study 36777426 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 36777695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0
Study 36777769 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance therapy plus best supportive care (CBSC)
Number of subjects: 0
Study 36777769 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 36778131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training of biofeedback and neurofeedback
Number of subjects: 0
Study 36778232 — intervention group
Group type: EXPERIMENTAL
Intervention: MAMA intervention
Number of subjects: 0
Study 36778375 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic median nerve stimulation (MNS) at 10 Hz
Number of subjects: 32
Study 36778375 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic median nerve stimulation (MNS) at 12 Hz
Number of subjects: 32
Study 36778375 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrhythmic median nerve stimulation (MNS) at 12 Hz
Number of subjects: 32
Study 36778375 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 32
Study 36778595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical supplements with yeast β-glucan, prebiotics, minerals
Number of subjects: 0
Study 36778864 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg subcutaneously every 12 hours for 3 days, then 100 mg subcutaneously once daily for 4 days) in addition to standard of care (SOC)
Number of subjects: 80
Study 36778864 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 80
Study 36779003 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor (Fitbit Charge 3) and custom weekly surveys
Number of subjects: 28
Study 36779003 — intervention group
Group type: COMPARATOR
Intervention: Pre-pandemic period
Number of subjects: 28
Study 36779257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone 42 mg
Number of subjects: 529
Study 36779257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone 28 mg
Number of subjects: 529
Study 36779257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 36779325 — intervention group
Group type: EXPERIMENTAL
Intervention: Hodgkin lymphoma treatment
Number of subjects: 6950
Study 36779342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongated cardiac computed tomography angiography (CTA)
Number of subjects: 370
Study 36779348 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 6635
Study 36779512 — intervention group
Group type: EXPERIMENTAL
Intervention: Magrolimab in combination with commonly used myeloma therapies
Number of subjects: 0
Study 36779614 — intervention group
Group type: EXPERIMENTAL
Intervention: Aragonite-based osteochondral implant
Number of subjects: 251
Study 36779614 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic debridement/microfractures (Control)
Number of subjects: 251
Study 36779823 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urine collection prior to stone removal
Number of subjects: 109
Study 36779823 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urine collection after stone removal
Number of subjects: 109
Study 36779823 — intervention group
Group type: COMPARATOR
Intervention: Comparison of urinary parameters before and after stone removal
Number of subjects: 109
Study 36779823 — intervention group
Group type: COMPARATOR
Intervention: Percentage of patients with clinically significant changes in urinary parameters
Number of subjects: 109
Study 36779911 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record (EHR)-based clinical decision support (CDS) tools for social risk screening and documentation.
Number of subjects: 0
Study 36779911 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS tools designed to support CHC providers and staff.
Number of subjects: 0
Study 36779982 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36780014 — intervention group
Group type: EXPERIMENTAL
Intervention: TFNA intramedullary nail
Number of subjects: 0
Study 36780014 — intervention group
Group type: COMPARATOR
Intervention: PFNA-II
Number of subjects: 0
Study 36780092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 430
Study 36780107 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 222
Study 36780114 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 174
Study 36780114 — intervention group
Group type: COMPARATOR
Intervention: Control (previous treatments: RG7800, olesoxime, nusinersen, onasemnogene abeparvovec)
Number of subjects: 174
Study 36780156 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (volar lock plating, percutaneous pinning, or external fixation)
Number of subjects: 293
Study 36780156 — intervention group
Group type: COMPARATOR
Intervention: Casting
Number of subjects: 293
Study 36780158 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultations
Number of subjects: 696
Study 36780158 — intervention group
Group type: COMPARATOR
Intervention: Telephone consultations
Number of subjects: 696
Study 36780161 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP cocktail + Δ9-THC
Number of subjects: 18
Study 36780161 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP cocktail + Δ9-THC + CBD
Number of subjects: 18
Study 36780161 — intervention group
Group type: COMPARATOR
Intervention: CYP cocktail + placebo
Number of subjects: 18
Study 36780159 — intervention group
Group type: EXPERIMENTAL
Intervention: SER-109 (4 capsules daily for 3 days after symptom resolution following antibiotic treatment)
Number of subjects: 263
Study 36780159 — intervention group
Group type: EXPERIMENTAL
Intervention: SER-109
Number of subjects: 263
Study 36780180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU per day of oral vitamin D3 supplementation
Number of subjects: 139
Study 36780180 — intervention group
Group type: COMPARATOR
Intervention: 400 IU per day of oral vitamin D3 supplementation
Number of subjects: 139
Study 36780210 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week low-sodium diet intervention with individual sessions via videoconferencing
Number of subjects: 40
Study 36780210 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week low-sodium diet intervention
Number of subjects: 40
Study 36780210 — intervention group
Group type: COMPARATOR
Intervention: Standard care for hypertension management (control group)
Number of subjects: 40
Study 36780211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsewatch system (smartwatch and smartphone app) used for continuous monitoring of AF for up to 6 weeks.
Number of subjects: 90
Study 36780265 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective Skills to Empower Effective Men (ESTEEM); an LGBQ-affirmative transdiagnostic cognitive behavioral therapy (CBT)
Number of subjects: 0
Study 36780265 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36780377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function test, maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), core stability tests, lumbopelvic stability test (LST), 2-minute walk test (2MWT), Timed Up and Go test (TUG)
Number of subjects: 30
Study 36780377 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals, N=30
Number of subjects: 30
Study 36780493 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600mg FCZ
Number of subjects: 168
Study 36780493 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000mg FCZ
Number of subjects: 168
Study 36780493 — intervention group
Group type: COMPARATOR
Intervention: AMB
Number of subjects: 168
Study 36780608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and relatlimab
Number of subjects: 518
Study 36780610 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DXd 5.4 mg/kg intravenously once every 3 weeks (n = 373)
Number of subjects: 557
Study 36780610 — intervention group
Group type: COMPARATOR
Intervention: Physicians' choice of chemotherapy (n = 184)
Number of subjects: 557
Study 36780674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection
Number of subjects: 697
Study 36780674 — intervention group
Group type: COMPARATOR
Intervention: Lobar resection
Number of subjects: 697
Study 36780675 — intervention group
Group type: EXPERIMENTAL
Intervention: Difelikefalin 2 mg orally twice daily for 8 weeks
Number of subjects: 126
Study 36780675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 36780675 — intervention group
Group type: EXPERIMENTAL
Intervention: Difelikefalin
Number of subjects: 126
Study 36780676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda (single subcutaneous injection, 180 μg)
Number of subjects: 1951
Study 36780676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single injection or oral)
Number of subjects: 1951
Study 36780676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda
Number of subjects: 1951
Study 36780768 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdose Education and Naloxone Distribution (OEND) strategies
Number of subjects: 33
Study 36780768 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Treatment for Opioid Use Disorder (MOUD) strategies
Number of subjects: 33
Study 36780768 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer Prescribing and Dispensing Practices (SPDP) strategies
Number of subjects: 33
Study 36780768 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall strategy selection
Number of subjects: 33
Study 36780768 — intervention group
Group type: COMPARATOR
Intervention: OEND and MOUD strategy selection
Number of subjects: 33
Study 36780810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training
Number of subjects: 76
Study 36780810 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 76
Study 36780943 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy protein + walking exercise
Number of subjects: 104
Study 36780943 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study 36781102 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab
Number of subjects: 29
Study 36781156 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN2 model
Number of subjects: 170
Study 36781334 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019 (two doses administered intramuscularly 21 days apart)
Number of subjects: 691
Study 36781334 — intervention group
Group type: COMPARATOR
Intervention: SCB-2019 (one dose administered)
Number of subjects: 691
Study 36781334 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019
Number of subjects: 691
Study 36781422 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of oxidative balance score (OBS)
Number of subjects: 18561
Study 36781451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexiganan (NCT01594762, 2012-05-07)
Number of subjects: 0
Study 36781451 — intervention group
Group type: EXPERIMENTAL
Intervention: Omiganan (NCT02576847, 2015-10-13)
Number of subjects: 0
Study 36781469 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronase administration
Number of subjects: 955
Study 36781469 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pronase administration)
Number of subjects: 955
Study 36781590 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate temporization (IT)
Number of subjects: 20
Study 36781590 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTG) with no temporization
Number of subjects: 20
Study 36781617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration training program (8 weeks, 3 sessions per week)
Number of subjects: 48
Study 36781617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration training program
Number of subjects: 48
Study 36781617 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal lifestyle)
Number of subjects: 48
Study 36781774 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor-based hematopoietic cell mobilization combined with granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 23
Study 36781774 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor-based mobilization
Number of subjects: 23
Study 36781928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate plus aspirin (300 mg orally once per day for 6 months)
Number of subjects: 272
Study 36781928 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin (75 mg orally once per day for 6 months)
Number of subjects: 272
Study 36782059 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SCN4A variants
Number of subjects: 0
Study 36782059 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 36782093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 787
Study 36782093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 787
Study 36782093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study 36782093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg and 400 mg
Number of subjects: 787
Study 36782134 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer survivors' recollections of their illness and treatment experiences after therapy
Number of subjects: 96